

Personal Information

Name : Roel GW Verhaak
Email : roel.verhaak@jax.org
Website : <https://www.jax.org/research-and-faculty/research-labs/the-verhaak-lab>
Twitter : @roelverhaak

Professional experience

2016-current: Professor and associate director for computational biology, The Jackson Laboratory for Genomic Medicine, Farmington, CT
2015-2016: Associate professor, Department of Bioinformatics and Computational Biology (primary), Department of Genomic Medicine (affiliate), UT MD Anderson Cancer Center, Houston, TX.
2013-2015: Assistant professor, Department of Genomic Medicine, UT MD Anderson Cancer Center, Houston, TX.
2010-2015: Assistant professor, Department of Bioinformatics and Computational Biology, UT MD Anderson Cancer Center, Houston, TX.
2010: Computational biologist, Laboratory of Matthew Meyerson, Broad Institute of MIT and Harvard, Cambridge, MA.
2006-2007: Research Scientist, Laboratory of Peter JM Valk, Department of Hematology, Erasmus Medical Center, Rotterdam, the Netherlands.
2002-2003: Software engineer, Dalicon BV, Nijmegen, the Netherlands.

Education

2006: PhD, Medicine, Erasmus University Medical Center, Rotterdam, the Netherlands. Thesis title: "Gene expression profiling of Acute Myeloid Leukemia." PhD-supervisors: Prof.Dr. Bob Löwenberg, Dr. Peter JM Valk.
2000: MSc, Biomedical Sciences, Radboud University, Nijmegen, the Netherlands.

Postdoctoral Training

2007-2010: Postdoctoral Fellow, Laboratory of Matthew Meyerson, Department of Medical Oncology, Dana-Farber Cancer Institute/Broad Institute of MIT and Harvard, Cambridge MA.
2006: Visiting Scientist, Laboratory of John Quackenbush. Department of Biostatistics and Computational Biology, Dana-Farber Cancer Institute. Boston, MA.

Research Fellowships:

2008-2010: Fundamental and pre-clinical fellowship, Dutch Cancer Society KWF
2006: Netherlands Genomics Initiative Fellowship

Awards & Honors

2016: Agilent Early Career Professor Award
2016: AAAS Martin and Rose Wachtel Cancer Research Award
2015: Finalist, Robert M. Chamberlain Distinguished Mentor Award.
2014: Adult Basic Science Award, Society for Neuro-Oncology Meeting 2014
2013: Pediatric Brain Tumor Foundation, Peter Steck Memorial Award

2011: Wilson S. Stone Memorial Award at MD Anderson's Symposia on Cancer Research

Current Lab

Hoon Kim, PhD, senior scientist, 06/11
Floris Barthel, MD, graduate student, VU Medical Center, the Netherlands, 02/14
Xin Hu, graduate student, University of Texas Graduate School of Biological Sciences, 11/13
Samirkumar Amin, graduate student, (Graduate Program in Structural and Computational Biology & Molecular Biophysics, Baylor College of Medicine), 06/15
Qianghu Wang, PhD, postdoctoral associate, 06/13
Emmanuel Martinez-Ledesma, PhD, postdoctoral associate, 09/14
Ze-yan Zhang, PhD, postdoctoral associate, 03/16
Soo Hyun Lee, MD, PhD, postdoctoral fellow, 05/16
Kevin Johnson, PhD, postdoctoral associate, 09/16

Lab Alumni

Wandaliz Torres-Garcia, PhD (postdoctoral associate; current: assistant professor, University of Puerto Rico), 06/11-06/13
Rahul Vegesna (programmer; current: graduate student, Penn State University) 06/11-06/13
Saman Amini (student trainee; current: graduate student, Utrecht University, the Netherlands) 02/12-06/12
Kosuke Yoshihara, MD, PhD (postdoctoral fellow; current: assistant professor, Niigata University Medical School, Japan), 01/12-06/14
Ji-Yeon Yang, PhD (biostatistical analyst; current: assistant professor, Kumoh National Institute of Technology, Korea), 06/12-12/13
Eskil Eskilsson, PhD, (postdoctoral associate; current: business school), 01/15 - 07/16
Siyuan Zheng, PhD, (instructor; current: instructor, UT MD Anderson Cancer Center), 05/11-09/16
Ming Tang, PhD, (postdoctoral associate; current: postdoctoral associate, UT MD Anderson Cancer Center), 03/15-09/16

Invited Speaker

2016: German Cancer Center, Heidelberg, Germany
2016: Samsung Medical Center, Seoul, South-Korea
2016: Radboud University Medical Center, Nijmegen, the Netherlands
2016: VU Medical Center, Amsterdam, the Netherlands
2016: Dartmouth College, Hanover, NH
2015: Society for Neuro-Oncology 2015 Annual Meeting, San Antonio, TX
2015: Samsung Medical Center, Seoul, South-Korea
2015: American Brain Tumor Association Alumni Research Network meeting, Chicago, IL
2015: Keynote Speaker, II International Symposium on Clinical and Basic Investigation in Glioblastoma, Toledo, Spain
2015: Keynote Speaker, Brain Tumor Epidemiology Consortium (BTEC) meeting,
2015: Spanish National Cancer Research Centre (CNIO), Madrid, Spain
2015: Cedar-Sinai Medical Center, Los Angeles, CA

2015: Seminars in Oncology, Dana-Farber Cancer Institute, Boston, MA
2014: Department of Neurosurgery, University of California San Francisco, San Francisco, CA
2014: Einstein Circle GBM Biology, Berlin, Germany
2014: VU Medical Center, Amsterdam, The Netherlands
2014: ASCO Genitourinary Cancers Symposium, San Francisco, CA
2013: The Cancer Genome Atlas Steering Committee meeting, Bethesda, MD
2013: Symposia on Cancer Research 2013: Genomic Medicine, Houston,
2013: Department of Medical Oncology, University Medical Center Utrecht, Utrecht, the Netherlands
2013: NCI Workshop: Correlating imaging phenotypes with genomic signatures, Bethesda, MD
2012: Department of Genetics, Baylor College of Medicine, Houston, TX
2012: NCI Clinical Proteomic Technologies for Cancer Steering Committee meeting, Houston, TX
2012: 1st Brazilian Genome Conference, Foz do Iguacu, Brazil
2012: 58th Brazilian Congress of Genetics, Foz do Iguacu, Brazil
2012: 21st Annual Symposium on Molecular Pathology, Troy, MI
2012: The Cancer Genome Atlas Pan-cancer comparison meeting, Santa Cruz, CA
2012: Memorial Sloan-Kettering Brain Tumor Center, New York, NY
2012: Ontario Cancer Institute, Toronto, CA
2011: Center for Molecular Medicine, Vienna, Austria
2011: "New roles for the EGFR Family in Cancer" Symposium, MD Anderson Cancer Center, Houston, TX
2011: Grand Rounds, University of Michigan, Ann Arbor, MI
2011: NRCI Cancer Conference 2011, Liverpool, UK
2010: Department of Bioinformatics and Computational Biology, MD Anderson Cancer Center, Houston, TX
2010: Netherlands Cancer Institute
2010: Computational Biology Center, Memorial Sloan Kettering Center, New York, NY
2009: The Cancer Genome Atlas meeting on glioblastoma, San Diego, CA
2008: NUS Cancer Research Centre of Excellence, Singapore
2005: Department of Hemato-oncology, Beth Israel Deaconess Medical Center, Boston, MA
2004: 4th VIB Microarray Users Group Meeting, Brussels, Belgium
2004: CBSB Symposium on Bioinformatics in microarrays research, Amsterdam, the Netherlands

Selected Abstract

2015: Society for Neuro-Oncology 2015 Annual Meeting, San Antonio, TX
2014: Society for Neuro-Oncology 2014 Annual Meeting, Miami, FL
2014: 20th International Conference on Brain Tumor Research and Therapy, Lake Tahoe, CA

- 2014: American Association for Cancer Research Annual Meeting, San Diego, CA
 2013: Society for Neuro-Oncology 2013 Annual Meeting, San Francisco, CA
 2012: Society for Neuro-Oncology 2012 Annual Meeting, Washington, DC
 2012: 2nd Scientific Meeting of The Cancer Genome Atlas, Washington, DC
 On Youtube: http://www.youtube.com/watch?v=vn_UoDMXKbc
 2005: 6th International Symposium and Expert Workshops on Leukemia and Lymphoma. Amsterdam, the Netherlands.
 2004: Myeloid Development Meeting. San Diego, CA

Current Research Support

1. NIH/NCI 5 U24 CA143883 04 (PI: Weinstein) 9/29/2009-7/31/2016
Role: Investigator, 5% effort
2. NIH/NCI P01CA085878-10A1 (PI: Ross) 7/01/2013-6/30/2018
Role: Bioinformatics Core leader, 20% effort
3. NIH/NCI SPORE in Brain Cancer (PI: Lang) 9/1/2013-8/31/2018
Role: Principal Investigator, Project 2 & Bioinformatics Core, 10% effort
4. NIH/NCI R01 CA190121 (PI: Verhaak) 9/1/2014-8/31/2018
Role: Principal Investigator, 10% effort
5. CPRIT R140606 Individual Investigator Award (PI: Verhaak) 8/31/2014-8/30/2017
Role: Principal Investigator, 20% effort
6. MD Anderson Multi-Disciplinary Research Program (PI: Draetta) 4/1/2014-03/31/2017
Role: Principal Investigator, Project 4 & Bioinformatics Core, 0% effort
7. National Brain Tumor Society, Defeat GBM Program (PI: Yung) 7/1/2014-/30/2019
Role: Co-investigator, 1% effort
8. MD Anderson AML/MDS Moon Shot Program (PI: Garcia-Manero) 9/12/2014-8/31/2018
Role: Co-investigator, 10% effort
9. National Brain Tumor Society Oligo Research Fund (PI: Verhaak) 6/1/2016-5/31/2019
Role: Principal Investigator, 10% effort

Bibliography

† Corresponding author

* Contributed equally

‡ Member of manuscript committee

Google Scholar Citation Page: <http://scholar.google.com/citations?user=qXdBk-gAAAAJ&hl=en&oi=ao>

1. Zheng S, Cherniack AD, Dewal N, Moffitt RA, Danilova L, Murray BA, Lerario AM, Else T, Knijnenburg TA, Ciriello G, Kim S, Assie G, Morozova O, Akbani R, Shih J, Hoadley KA, Choueiri TK, Waldmann J, Mete O, Robertson AG, Wu HT, Raphael BJ, Shao L, Meyerson M, Demeure MJ, Beuschlein F, Gill AJ, Sidhu SB, Almeida MQ, Fragoso MC, Cope LM, Kebebew E, Habra MA, Whitsett TG, Bussey KJ, Rainey WE, Asa SL, Bertherat J, Fassnacht M, Wheeler DA; Cancer Genome Atlas Research Network, Hammer GD, Giordano TJ†, **Verhaak RG†**.
Comprehensive Pan-Genomic Characterization of Adrenocortical Carcinoma. *Cancer Cell*. 2016 May 9;29(5):723-36. doi: 10.1016/j.ccell.2016.04.002.
2. Ceccarelli C, Barthel FP, Malta TM, Sabedot TS, Salama SR, Murray BA, Morozova O, Newton Y, Radenbaugh A, Pagnotta SM, Anjum A, Wang J, Manyam G, Zoppoli P, Ling Y,

Rao A, Grifford M, Cherniack AD, Zhang H, Poisson L, Carlotti Junior CG, Da Cunha Tirapelli PP, Rao A, Mikkelsen T, Lau CC, Yung WK, Rabadan R, Huse J, Brat DJ, Lehman N, Barnholtz-Sloan JS, Zheng S, Hess H, Rao G, Meyerson M, Beroukhir R, Cooper L, Akbani R, Wrensch M, Haussler D, Aldape KD, Laird PW, Gutmann DH, TCGA Research Network, Noushmehr H†, Iavarone A†, **Verhaak RG†**.

Molecular profiling reveals biologically discrete subsets and pathways of progression in diffuse glioma.

Cell 164, 1–14 January 28, 2016.

3. Alizadeh AA, Aranda V, Bardelli A, Blanpain C, Bock C, Borowski C, Caldas C, Califano A, Doherty M, Elsner M, Esteller M, Fitzgerald R, Korbel JO, Lichter P, Mason CE, Navin N, Pe'er D, Polyak K, Roberts CW, Siu L, Snyder A, Stower H, Swanton C, **Verhaak RG**, Zenklusen JC, Zuber J, Zucman-Rossi J.
Toward understanding and exploiting tumor heterogeneity.
Nat Med. 2015 Aug;21(8):846-53. doi: 10.1038/nm.3915. PMID: 26248267
4. TCGA Research Network; Brat DJ‡, **Verhaak RG‡**, Aldape KD‡, et al.
Comprehensive Integrative Genomic Analysis of Diffuse Lower Grade Gliomas.
N Engl J Med. 2015 Jun 25;372(26):2481-98. doi: 10.1056/NEJMoa1402121. Epub 2015 Jun 10. PMID: 26061751
5. Kim H, **Verhaak RG†**.
Transcriptional mimicry by tumor associated stroma inflated the EMT hypothesis.
Nat Genet. 2015 Apr;47(4):307-9. doi: 10.1038/ng.3255. PMID: 25814306
Invited News&Views
6. Martinez-Ledesma E, De Groot JF, **Verhaak RG†**.
Seek and destroy: relating cancer drivers to therapies.
Cancer Cell. 2015 Mar 9;27(3):319-21. doi: 10.1016/j.ccell.2015.02.011.
Invited Preview
7. Kim H, Zheng S, Amini SS, Virk SM, Mikkelsen T, Brat DJ, Grimsby J, Sougnez C, Muller F, Hu J, Sloan AE, Cohen ML, Van Meir EG, Scarpance L, Laird PW, Weinstein JN, Lander E, Gabriel S, Getz G, Meyerson M, Chin L, Barnholtz-Sloan JS, **Verhaak RG†**.
Whole genome and multi-sector exome sequencing of primary and post-treatment glioblastoma reveals patterns of tumor evolution.
Genome Research. 2015 Feb 3. pii: gr.180612.114. PMID: 25650244
8. Yoshihara K, **Verhaak RG†**.
Hiding in the dark: uncovering cancer drivers through image-guided genomics.
Genome Biol. 2014 Dec 20;15(12):563. doi: 10.1186/s13059-014-0563-3. PMID: 25608759
Invited Research Highlight
9. Yoshihara K, Wang Q, Torres-Garcia W, Zheng S, Vegesna R, Kim H, **Verhaak RG†**.
The landscape and therapeutic relevance of cancer-associated transcript fusions.
Oncogene. 2015 Sep 10;34(37):4845-54. doi: 10.1038/onc.2014.406. Epub 2014 Dec 15. PMID: 25500544

10. Martínez E, Yoshihara K, Kim H, Mills GM, Treviño V, **Verhaak RG†**.
Comparison of gene expression patterns across 12 tumor types identifies a cancer supercluster characterized by TP53 mutations and cell cycle defects.
Oncogene. 2015 May 21;34(21):2732-40. doi: 10.1038/onc.2014.216. Epub 2014 Aug 4. PMID: 25088195
11. Torres-García W, Zheng S, Sivachenko A, Vegesna R, Wang Q, Yao R, Berger MF, Weinstein JN, Getz G†, **Verhaak RG†**.
PRADA: pipeline for RNA sequencing data analysis.
Bioinformatics. 2014 Aug 1;30(15):2224-6. doi: 10.1093/bioinformatics/btu169. Epub 2014 Apr 1. PMID: 24695405
12. Zheng S, Kim H, **Verhaak RG†**.
Silent mutations make some noise.
Cell. 2014 Mar 13;156(6):1129-31. doi: 10.1016/j.cell.2014.02.037. PMID: 24630716
13. Guan X, Vengoechea J, Zheng S, Sloan AE, Chen Y, Brat DJ, O'Neill BP, de Groot J, Yust-Katz S, Yung WK, Cohen ML, Aldape KD, Rosenfeld S, **Verhaak RG†**, Barnholtz-Sloan JSt.
Molecular subtypes of glioblastoma are relevant to lower grade glioma.
PLoS One. 2014 Mar 10;9(3):e91216. doi: 10.1371/journal.pone.0091216. eCollection 2014. PMID: 24614622
14. Zheng S, **Verhaak RG†**.
Intragenic breakpoint: a marker of genome instability in glioblastoma.
Cell Cycle. 2013 Dec 15;12(24):3705-6. doi: 10.4161/cc.26874. Epub 2013 Oct 21. No abstract available. PMID: 24145229
15. Brennan CW*, **Verhaak RG***, McKenna A*, et al.
The somatic genomic landscape of glioblastoma.
Cell. 2013 Oct 10;155(2):462-77. doi: 10.1016/j.cell.2013.09.034. PMID: 24120142
16. Yoshihara K, Shahmoradgoli M, Martínez E, Vegesna R, Kim H, Torres-Garcia W, Treviño V, Shen H, Laird PW, Levine DA, Carter SL, Getz G, Stemke-Hale K, Mills GB, **Verhaak RG†**.
Inferring tumour purity and stromal and immune cell admixture from expression data.
Nat Commun. 2013;4:2612. doi: 10.1038/ncomms3612. PMID: 24113773
17. Cancer Genome Atlas Research Network.
The Cancer Genome Atlas Pan-Cancer analysis project.
Nat Genet. 2013 Oct;45(10):1113-20. doi: 10.1038/ng.2764. PMID: 24071849
18. Yang JY, Yoshihara K, Tanaka K, Hatae M, Masuzaki H, Itamochi H; Cancer Genome Atlas (TCGA) Research Network, Takano M, Ushijima K, Tanyi JL, Coukos G, Lu Y, Mills GB, **Verhaak RG†**.
Predicting time to ovarian carcinoma recurrence using protein markers.

J Clin Invest. 2013 Sep;123(9):3740-50. doi: 10.1172/JCI68509. Epub 2013 Aug 15. PMID: 23945238

Genomeweb:

<http://www.genomeweb.com/clinical-genomics/tcga-protein-data-yields-predictive-signature-ovarian-cancer-recurrence>

Covered in Japans' second largest newspaper (in Japanese):

<http://www.asahi.com/shimen/articles/TKY201308150550.html>

19. Zheng S, Fu J, Vegesna R, Mao Y, Heathcock LE, Torres-Garcia W, Ezhilarasan R, Wang S, McKenna A, Chin L, Brennan CW, Yung WK, Weinstein JN, Aldape KD, Sulman EP, Chen K, Koul D, **Verhaak RG†**.
A survey of intragenic breakpoints in glioblastoma identifies a distinct subset associated with poor survival.
Genes Dev. 2013 Jul 1;27(13):1462-72. doi: 10.1101/gad.213686.113. Epub 2013 Jun 24. PMID: 23796897
20. Cancer Genome Atlas Research Network[‡].
Comprehensive molecular characterization of clear cell renal cell carcinoma.
Nature. 2013 Jul 4;499(7456):43-9. doi: 10.1038/nature12222. Epub 2013 Jun 23. PMID: 23792563
21. **Verhaak RG†**, Tamayo P, Yang JY, et al.
Prognostically relevant gene signatures of high-grade serous ovarian carcinoma.
J Clin Invest. 2013 Jan;123(1):517-25. doi: 10.1172/JCI65833. Epub 2012 Dec 21. PMID: 23257362
Genomeweb item:
<http://www.genomeweb.com/cancer-genome-atlas-research-data-researchers-refine-prognostic-signatures-ovari>
Nature Reviews Clinical Oncology Perspective :
<http://www.nature.com/nrclinonc/journal/v10/n2/full/nrclinonc.2013.2.html>
22. **Verhaak RG†**, Mills GB.
Regulation of mRNA expression in breast cancer - a cis-tematic trans-action.
Breast Cancer Res. 2012 Oct 29;14(5):322. doi: 10.1186/bcr3227. PMID: 23106814
23. Zong H, **Verhaak RG**, Canoll P.
The cellular origin for malignant glioma and prospects for clinical advancements.
Expert Rev Mol Diagn. 2012 May;12(4):383-94. doi: 10.1586/erm.12.30. Review. PMID: 22616703
24. Zheng S, Chheda MG, **Verhaak RG†**.
Studying a complex tumor: potential and pitfalls.
Cancer J. 2012 Jan-Feb;18(1):107-14. doi: 10.1097/PPO.0b013e3182431c57. Review. PMID: 22290264
25. Cancer Genome Atlas Research Network[‡].
Integrated genomic analyses of ovarian carcinoma.

- Nature. 2011 Jun 29;474(7353):609-15. doi: 10.1038/nature10166PMID: 21720365
26. Winslow MM, Dayton TL, **Verhaak RG**, et al.
Suppression of lung adenocarcinoma progression by Nkx2-1.
Nature. 2011 May 5;473(7345):101-4. doi: 10.1038/nature09881. Epub 2011 Apr 6. PMID: 21471965
27. Wang XV, **Verhaak RG**, Purdom E, et al.
Unifying gene expression measures from multiple platforms using factor analysis.
PLoS One. 2011 Mar 11;6(3):e17691. doi: 10.1371/journal.pone.0017691. PMID: 21436879
28. Noushmehr H, Weisenberger DJ, Diefes K, et al.
Identification of a CpG island methylator phenotype that defines a distinct subgroup of glioma.
Cancer Cell. 2010 May 18;17(5):510-22. doi: 10.1016/j.ccr.2010.03.017. Epub 2010 Apr 15. PMID: 20399149
29. **Verhaak RG***, Hoadley KA*, Purdom E, et al.
Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1.
Cancer Cell. 2010 Jan 19;17(1):98-110. doi: 10.1016/j.ccr.2009.12.020. PMID: 20129251
Press release with comments from Francis Collins, John Niederhuber and Eric Green:
<http://cancergenome.nih.gov/newsevents/newsannouncements/glioblastoma4subtypes>
Nature News: <http://www.nature.com/news/2010/100120/full/463278a.html>
30. **Verhaak RG**, Valk PJ.
Genes predictive of outcome and novel molecular classification schemes in adult acute myeloid leukemia.
Cancer Treat Res. 2010;145:67-83. doi: 10.1007/978-0-387-69259-3_5. Review. PMID: 20306246
31. **Verhaak RG***, Wouters BJ*, Erpelinck CA, et al.
Prediction of molecular subtypes in acute myeloid leukemia based on gene expression profiling.
Haematologica. 2009 Jan;94(1):131-4. doi: 10.3324/haematol.13299. Epub 2008 Oct 6. PMID: 18838472
32. Cancer Genome Atlas Research Network*.
Comprehensive genomic characterization defines human glioblastoma genes and core pathways.
Nature. 2008 Oct 23;455(7216):1061-8. doi: 10.1038/nature07385. Epub 2008 Sep 4. PMID: 18772890

33. Sanders MA, **Verhaak RG**, Geertsma-Kleinekoort WM, et al.
SNPEXpress: integrated visualization of genome-wide genotypes, copy numbers and gene expression levels.
BMC Genomics. 2008 Jan 25;9:41. doi: 10.1186/1471-2164-9-41. PMID: 18221515
34. Steidl U, Rosenbauer F, **Verhaak RG**, et al.
Essential role of Jun family transcription factors in PU.1 knockdown-induced leukemic stem cells.
Nat Genet. 2006 Nov;38(11):1269-77. Epub 2006 Oct 15. PMID: 17041602
35. **Verhaak RG**, Sanders MA, Bijl MA, et al.
HeatMapper: powerful combined visualization of gene expression profile correlations, genotypes, phenotypes and sample characteristics.
BMC Bioinformatics. 2006 Jul 12;7:337. PMID: 16836741
36. **Verhaak RG**, Staal FJ, Valk PJ, et al.
The effect of oligonucleotide microarray data pre-processing on the analysis of patient-cohort studies.
Bioinformatics. 2006 Mar 2;7:105. PMID: 16512908
37. Erkeland SJ*, **Verhaak RG***, Valk PJ, et al.
Significance of murine retroviral mutagenesis for identification of disease genes in human acute myeloid leukemia.
Cancer Res. 2006 Jan 15;66(2):622-6. PMID: 16423987
38. **Verhaak RG**, Goudswaard CS, van Putten W, et al.
Mutations in nucleophosmin (NPM1) in acute myeloid leukemia (AML): association with other gene abnormalities and previously established gene expression signatures and their favorable prognostic significance.
Blood. 2005 Dec 1;106(12):3747-54. Epub 2005 Aug 18. PMID: 16109776
39. Valk PJ, **Verhaak RG**, Beijnen MA, et al.
Prognostically useful gene-expression profiles in acute myeloid leukemia.
N Engl J Med. 2004 Apr 15;350(16):1617-28. PMID: 15084694